French limit conditions and prices for heart leads
This article was originally published in Clinica
Executive Summary
Manufacturers of leads used in implantable heart stimulation devices, such as pacemakers, have until March 2 to comment on two proposals just published in the French Journal officiel that will impact conditions for reimbursement and the prices they can charge. The first of the two proposals, drafted by the French commission responsible for the evaluation of healthcare products and services, CEPP, lists the various conditions of use which must be met when the various leads are implanted. The second, drafted by the healthcare products pricing committee, the CEPS, proposes upper limits of prices that can be charged and reimbursed for these different types of leads, which are set at E540 ($654) for most leads except for those used in transvenous stimulation, which are set at E850. The proposals were published in the JO on January 31.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.